Form 4: Monopar CEO Reports RSU Vesting and Equity Changes
Insider Transaction Report
Monopar Therapeutics CEO Chandler Robinson reported the vesting of restricted stock units and associated tax-related share dispositions, increasing direct common stock holdings.
Summary
- Chandler Robinson, CEO and Director of Monopar Therapeutics (MNPR), reported transactions on September 30, 2025.
- Acquired 8,726 shares of common stock through the vesting and settlement of restricted stock units (RSUs).
- Disposed of 2,646 shares of common stock at a price of $81.67 per share to cover applicable withholding taxes upon RSU vesting.
- Following these transactions, direct beneficial ownership of common stock stands at 79,552 shares.
- Indirect beneficial ownership remains at 272,026 shares through Tactic Pharma LLC, with Dr. Robinson disclaiming beneficial ownership except for his pecuniary interest.
- Remaining derivative securities include 72,599 directly held restricted stock units.
Sentiment
Score: 6
Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax withholding). These are expected events and do not indicate significant positive or negative operational or financial news for the company, hence a neutral to slightly positive score reflecting the executive's continued equity accumulation.
Positives
- The vesting of 8,726 restricted stock units demonstrates the continued execution of the executive compensation plan, aligning management interests with shareholder value.
- An increase in direct common stock holdings for the CEO, post-tax withholding, indicates ongoing equity accumulation.
Negatives
- A disposition of 2,646 shares was necessary to cover tax obligations arising from the RSU vesting, which is a standard practice but reduces the immediate direct share count.
Future Outlook
Future equity acquisitions for the CEO are anticipated through the ongoing vesting schedules of previously granted restricted stock units, with vesting periods extending until December 31, 2025, December 31, 2026, and December 31, 2028, for various grants.
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency into executive equity ownership and compensation, which can influence investor confidence and perception of management alignment.
Next Steps
- Continued vesting of outstanding restricted stock units according to their respective schedules, with the next significant vesting dates occurring quarterly until December 31, 2028.
Key Dates
| Date | Description |
|---|---|
| 2022-02-02 | Grant date for 31,905 restricted stock units, vesting until December 31, 2025. |
| 2023-02-01 | Grant date for 33,803 restricted stock units, vesting until December 31, 2026. |
| 2025-03-04 | Grant date for 79,899 restricted stock units, with 6,002 shares vesting immediately and the remainder vesting until December 31, 2028. |
| 2025-09-30 | Transaction date for the vesting and settlement of restricted stock units and associated tax withholding. |
| 2025-10-02 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Monopar Therapeutics, MNPR, Insider Transaction, Form 4, Restricted Stock Units, CEO, Equity Ownership, Stock Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.